Fig. 1

a Flowchart describing molecular analyses of EM-patients. b Flowchart describing serological analyses of EM-patients. *Day 14 and 3-month sera were additionally analyzed for TBEV (187/188) and Bbsl (175/188), respectively. †Patients with detectable IgG in the screening sample also had the remaining study samples tested for antibodies against the corresponding microorganisms